Access to the Latest Treatments 

ClinicalTrials AdvancedOncology 028Oregon Urology Institute Radiation Center is deeply involved in clinical research to advance the standard of care in treating urological cancers. As a result, you have access to experimental procedures and treatments that wouldn’t otherwise be available. If you’d like to join a clinical trial, your doctor can help determine if you’re a candidate. If you qualify, you’ll be informed about potential risks and benefits. Our clinical trial participants are carefully monitored and can opt out at any time.
 
Here are trials we’re currently conducting. Ask your doctor for more information if you’re interested in participating.

 

 

Currently Enrolling

Prostate Cancer - GU-115

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Endpoint Classification: Efficacy Study
    • Intervention Model: Parallel Assignment
    • Masking: Double Blind (Subject, Investigator)
    • Primary Purpose: Treatment
  • Official Title:

    A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - EMBARK

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Endpoint Classification: Safety/Efficacy Study
    • Intervention Model: Parallel Assignment
    • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
    • Primary Purpose: Treatment
  • Official Title:

    A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy)

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - Atlas

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Endpoint Classification: Safety/Efficacy Study
    • Intervention Model: Parallel Assignment
    • Masking: Double Blind (Subject, Investigator)
    • Primary Purpose: Treatment
  • Official Title:

    ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - PROfound

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Open Label
    • Primary Purpose: Treatment
  • Official Title:

    A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - Tak-Rad

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
    • Primary Purpose: Treatment
  • Official Title:

    A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - TRUMPET

  • Study Type:

    Observational

  • Study Design:
    • Observational Model: Cohort
    • Time Perspective: Prospective
  • Official Title:

    A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - Ulyesses

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
    • Primary Purpose: Treatment
  • Official Title:

    A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer

  • For more information on this study visit clinicaltrials.gov

Bladder Cancer - Conquer

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Interventional Model Description: This is a randomized, multicenter, two-arm, double-blind, placebo-controlled study of Qapzola in patients with low- to intermediate-risk NMIBC.
    • Masking: Triple (Participant, Care Provider, Investigator)
    • Primary Purpose: Treatment
  • Official Title:

    A Randomized, Single-Dose, Double-Blind, Placebo-CONtrolled Phase 3 Study of Qapzola™ (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder Tumors in Patients With Low- To-Intermediate-Risk NMIBC (CONQUER)

  • For more information on this study visit clinicaltrials.gov

Ongoing Studies-Not Enrolling

Prostate Cancer - 09-023

  • Official Title:

    A PROSPECTIVE MULTICENTER OBSERVATIONAL TRIAL TO ASSESS PERSISTENCE ON ACTIVE SURVEILLANCE WHEN USING THE ONCOTYPE DX PROSTATE CANCER ASSAY

Prostate Cancer - MOLE

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Masking: No masking
    • Primary Purpose: Treatment
  • Official Title:

    A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - Xofigo

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Endpoint Classification: Safety/Efficacy Study
    • Intervention Model: Parallel Assignment
    • Masking: Open Label
    • Primary Purpose: Treatment
  • Official Title:

    A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - PASCUAL

  • Study Type:

    Observational

  • Study Design:
    • Observation Model: Case Control
    • Time Perspective: Prospective
  • Official Title:

    PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - REASSURE

  • Study Type:

    Observational

  • Study Design:
    • Observational Model: Cohort
    • Time Perspective: Prospective
  • Official Title:

    Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - ConfirmMDx

  • Official Title:

    A prospective study to evaluate the clinical utility of the ConfirmMDx® for Prostate Cancer assay for men with previous histologically-negative prostate biopsies

Prostate Cancer - PROSPER

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Endpoint Classification: Efficacy Study
    • Intervention Model: Parallel Assignment
    • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
    • Primary Purpose: Treatment
  • Official Title:

    A A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer

  • For more information on this study visit clinicaltrials.gov

Prostate Cancer - Titan

  • Study Type:

    Interventional

  • Study Design:
    • Allocation: Randomized
    • Endpoint Classification: Safety/Efficacy Study
    • Intervention Model: Parallel Assignment
    • Masking: Double Blind (Subject, Investigator)
    • Primary Purpose: Treatment
  • Official Title:

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  • For more information on this study visit clinicaltrials.gov
If you’d like to learn more about clinical trials in general, please visit clinicaltrials.gov.